**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Hepatology  
**Manuscript NO:** 66512  
**Title:** Direct Oral Anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?  
**Provenance and peer review:** Invited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 05842474  
**Position:** Peer Reviewer  
**Academic degree:** PhD  
**Professional title:** Academic Fellow, Doctor  
**Reviewer’s Country/Territory:** Greece  
**Author’s Country/Territory:** Italy  
**Manuscript submission date:** 2021-03-30  
**Reviewer chosen by:** AI Technique  
**Reviewer accepted review:** 2021-04-20 08:25  
**Reviewer performed review:** 2021-04-28 08:40  
**Review time:** 8 Days  

<table>
<thead>
<tr>
<th><strong>Scientific quality</strong></th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Language quality</strong></td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td><strong>Conclusion</strong></td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td><strong>Re-review</strong></td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The authors of this paper focus on a very interesting topic. They have conducted an extensive review of the bibliography and present the current state-of-the-art on portal vein thrombosis and the possible use of DOACs in the setting of liver cirrhosis. Their paper needs an extended linguistic revision by a native English speaker, because in many parts its syntax and grammar are confusing, at best, for the reader. What is more, in the previous four months two new meta-analyses (Nisly et al. J Thromb Thrombolysis Mar 2021 and Meninchelli et al Eur J Clin Invest Mar 2021) have added new information in the field, underlining the safety and efficacy of DOACs in cirrhosis. Finally, an excellent relevant recent study has been published in January 2021 in Hepatology. In this retrospective longitudinal study by Serper et al, the researchers have once more highlighted the safety of DOACs in patients with cirrhosis, using national data of US veterans with cirrhosis. Moreover, they observed a possible effect of DOACs in ameliorating all-cause mortality in patients with cirrhosis. Additionally, they also found that hepatic decompensation was lower with both warfarin and DOACs in analyses limited to marginal structural models. According to the reviewer, the authors should consider adding all three aforementioned articles in their paper.